Innate Pharma S.A. (EPA:IPH)

Innate Pharma Revenue

Innate Pharma had revenue of 2.43M EUR in the half year ending June 30, 2025, a decrease of -60.63%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.

• Revenue (ttm): 12.64M
• Revenue Growth: -62.60%
• P/S Ratio: 11.12
• Revenue / Employee: 72.62K
• Employees: 181
• Market Cap: 140.48M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	20.12M	-41.52M	-67.36%
Dec 31, 2023	61.64M	3.97M	6.88%
Dec 31, 2022	57.67M	32.97M	133.47%
Dec 31, 2021	24.70M	-45.07M	-64.60%
Dec 31, 2020	69.77M	-15.68M	-18.35%
Dec 31, 2019	85.45M	-8.50M	-9.05%
Dec 31, 2018	93.95M	49.92M	113.37%
Dec 31, 2017	44.03M	-21.69M	-33.00%
Dec 31, 2016	65.72M	40.58M	161.41%
Dec 31, 2015	25.14M	17.52M	229.80%
Dec 31, 2014	7.62M	-9.03M	-54.22%
Dec 31, 2013	16.65M	2.37M	16.59%
Dec 31, 2012	14.28M	-	-